STOCK TITAN

Amphastar Pharmaceuticals (AMPH) Stock News, May-Oct 2025

AMPH NASDAQ

Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, and also sells active pharmaceutical ingredient products. Its finished products are distributed through group purchasing organizations, drug wholesalers, and drug retailers, with many used in hospital or urgent care settings.

Company news commonly covers quarterly financial results, product sales trends for therapies such as BAQSIMI®, Primatene MIST®, glucagon and epinephrine products, FDA approvals and launches, and spending on insulin, inhalation, and proprietary pipeline programs. Updates also include licensing activity, including AMP-110, a fully synthetic corticotropin compound for inflammatory and autoimmune conditions, as well as healthcare conference presentations and corporate communications.

Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ: AMPH) said it will release results for its third quarter of 2025, which ended September 30, 2025, after market close on Thursday, November 6, 2025. The company will hold a conference call that day at 2:00 p.m. Pacific Time to discuss results, accessible by toll-free dial-in and via webcast on the company Investors page, with a replay posted within 24 hours.

The release reiterates forward-looking statements about product sales, development, regulatory timing, manufacturing capacity expansion, and other future events, and points readers to Amphastar's SEC filings for risk factors and additional details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
conferences
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company will be represented by CFO Bill Peters and SVP of Corp. Communication Dan Dischner in an analyst-moderated fireside chat.

The presentation is scheduled for Wednesday, September 3rd, 2025, at 12:45 pm ET. Investors can access the webcast through Amphastar's investor relations website at ir.amphastar.com, where it will remain available for 30 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology for three proprietary peptides in the US and Canada. The agreement includes an initial payment of $6 million ($0.75M earnest money + $5.25M upfront), with potential milestone payments reaching $453 million over the agreement's lifetime.

The licensed products include: 1) An endogenous peptide targeting multiple poorly treated cancers, 2) A novel peptide-docetaxel conjugate designed to improve taxane therapies, and 3) An anti-VEGFR peptide eye drop for wet age-related macular degeneration treatment. The agreement includes 5% royalty payments on net sales, capped at $60 million per Licensed Product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.93%
Tags
none
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) has received FDA approval for its generic Iron Sucrose Injection, USP (AMP-002), which is bioequivalent to Venofer® for treating iron deficiency anemia in chronic kidney disease patients. The approved product will be available in three dosage strengths: 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials.

The company plans to launch the product in Q3 2025. The reference drug Venofer® generated U.S. sales of approximately $513 million for the 12 months ended June 30, 2025. Amphastar's robust pipeline includes three ANDAs and one biosimilar insulin candidate targeting a $2.5 billion market, three biosimilar products targeting a $6 billion market, and two generic products targeting a $1 billion market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.91%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2025 financial results with net revenues of $174.4 million and GAAP net income of $31.0 million ($0.64 per share). The company's adjusted non-GAAP net income was $40.9 million ($0.85 per share).

BAQSIMI® emerged as a key revenue driver with a 51% increase to $46.7 million, while the company faced challenges with decreased sales in epinephrine (-42%) and glucagon (-25%). The company announced a major strategic initiative to quadruple manufacturing capacity at its Rancho Cucamonga headquarters. Additionally, the Board authorized a $50 million increase to the share buyback program.

The company's pipeline includes 4 ANDAs and one biosimilar insulin candidate filed with FDA, targeting products with a combined market size exceeding $3 billion, plus three biosimilar products targeting a $6 billion market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.13%
Tags
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) has scheduled its second quarter 2025 earnings release and conference call for August 7, 2025. The financial results will be released after market close, followed by a conference call at 2:00 p.m. Pacific Time.

Amphastar is a bio-pharmaceutical company specializing in developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company also produces insulin API products, with most of its finished products being used in hospital or urgent care clinical settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
conferences earnings
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga, California headquarters. The company plans to quadruple its production capacity over the next 3-5 years, marking its largest domestic infrastructure investment to date.

The expansion includes a new state-of-the-art production plant, enhanced automation, and advanced technologies integration to support critical medication production and pipeline candidates. The initiative will create new jobs across R&D, engineering, manufacturing, and quality operations. Notably, all of Amphastar's finished pharmaceutical products are manufactured in the U.S., reinforcing their commitment to domestic production and supply chain resilience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
none
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CFO Bill Peters and EVP of Corporate Administration Jacob Liawatidewi will engage in an analyst-moderated fireside chat on June 5th, 2025, at 2:00 pm ET. Investors can access the presentation through Amphastar's website at ir.amphastar.com, with the webcast remaining available for 30 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences
-
Rhea-AI Summary

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced that its CFO Bill Peters and SVP of Corp. Communication Dan Dischner will participate in a fireside chat at the 2025 Bank of America Health Care Conference. The presentation is scheduled for Wednesday, May 14th, 2025, at 1:40 pm PT. Investors can access the webcast through Amphastar's website at http://ir.amphastar.com, and the recording will remain available for 30 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
conferences
Rhea-AI Summary
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q1 2025 financial results with net revenues of $170.5M, slightly down 1% from $171.8M in Q1 2024. GAAP net income was $25.3M ($0.51 per share), compared to $43.2M ($0.81 per share) in Q1 2024. BAQSIMI® sales surged 177% to $38.4M, while Primatene MIST® grew 20% to $29.1M. However, Glucagon and Epinephrine sales declined 27% and 29% respectively due to increased competition. The company's pipeline includes 4 ANDAs and 1 biosimilar insulin candidate filed with FDA, targeting products with >$3B market size. The FDA's acceptance of AMP-004 insulin biosimilar application marks a significant milestone for their biosimilar portfolio expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags

FAQ

What is the current stock price of Amphastar Pharmaceuticals (AMPH)?

Amphastar Pharmaceuticals (AMPH) last closed at $29.10.

What is the market cap of Amphastar Pharmaceuticals (AMPH)?

The market cap of Amphastar Pharmaceuticals (AMPH) is approximately $1.2B.